WATSON TO PAY $70 MIL. UP FRONT FOR HMR's RUGBY GENERIC DIVISION; HOECHST DIVESTING GENERIC DIVISIONS BEFORE NYSE LISTING SCHEDULED FOR SEPT. 24
Executive Summary
Watson Pharmaceuticals is paying $70 mil. up front to acquire the Rugby generic business from Hoechst Marion Roussel, the companies announced Aug. 26.